2023 Dec;108(12):e1542-e1550 [PMC free article: PMC10655511] [PubMed: 37379033] 74
For many patients, taste changes are most noticeable during the initial weeks of treatment or following dose increases , often coinciding with the period when gastrointestinal adverse effects such as nausea are most prominent
What the human evidence looks like How many human studies exist The 2025 systematic review by Vasireddi, Hahamyan, Salata, and colleagues in HSS Journal is the most rigorous available assessment of the BPC-157 literature (19932024) for orthopedic and sports medicine applications
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
5,21 Furthermore, 24 months treatment with the anti-osteoporotic drugs denosumab (Dmab) and alendronate in T2D lead to improvements of bone mineral density (BMD), but Dmab also induced a modest improvement in glycaemic control when compared to alendronate
Procedure codes drive reimbursement